284492-02-0 Usage
General Description
3-N-FMOC-3-(4-Methoxyphenyl)propionic acid is a chemical compound used in organic synthesis and pharmaceutical research. It is a derivative of 3-(4-Methoxyphenyl)propionic acid, which is a nonsteroidal anti-inflammatory drug (NSAID) with analgesic and antipyretic properties. The addition of the 9-fluorenylmethoxycarbonyl (FMOC) protecting group to the 3-position of the propionic acid moiety is commonly used in peptide chemistry to protect the carboxyl group. 3-N-FMOC-3-(4-METHOXYPHENYL)PROPIONIC ACID can be used as a building block in the synthesis of various peptides and pharmaceutical compounds, as well as in the study and development of drug delivery systems and targeted therapies. Its chemical structure and reactivity make it a valuable tool in the fields of medicinal and organic chemistry.
Check Digit Verification of cas no
The CAS Registry Mumber 284492-02-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,8,4,4,9 and 2 respectively; the second part has 2 digits, 0 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 284492-02:
(8*2)+(7*8)+(6*4)+(5*4)+(4*9)+(3*2)+(2*0)+(1*2)=160
160 % 10 = 0
So 284492-02-0 is a valid CAS Registry Number.
InChI:InChI=1/C25H23NO5/c1-30-17-12-10-16(11-13-17)23(14-24(27)28)26-25(29)31-15-22-20-8-4-2-6-18(20)19-7-3-5-9-21(19)22/h2-13,22-23H,14-15H2,1H3,(H,26,29)(H,27,28)
284492-02-0Relevant articles and documents
Solid-phase synthesis of a nonpeptide RGD mimetic library: New selective αvβ3 integrin antagonists
Sulyok,Gibson,Goodman,H?lzemann,Wiesner,Kessler
, p. 1938 - 1950 (2007/10/03)
The solid-phase synthesis of a low molecular weight RGD mimetic library is described. Activities of the compounds in inhibiting the interaction of ligands, vitronectin and fibrinogen, with isolated immobilized integrins αvβ3 and αIIbβ3 were determined in a screening assay. Highly active and selective nonpeptide αvβ3 integrin antagonists with regard to orally bioavailability were developed, based on the aza-glycine containing lead compound 1. An important variation is the substitution of the aspartic amide of 1 by an aromatic residue. Furthermore, different guanidine mimetics have been incorporated to improve the pharmacokinetic profile. Exchange of the β-amino acid NH by a methylene moiety in one set of RGD mimetics leads to the azacarba analogue compounds representing a novel peptidomimetic approach, which should increase the metabolic stability.
